These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26589792)

  • 1. Treatment regimens of classical and newer taxanes.
    Joerger M
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):221-33. PubMed ID: 26589792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of the taxanes including nab-paclitaxel.
    Joerger M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of TDM-based dose adjustments for taxane anticancer drugs.
    Muth M; Ojara FW; Kloft C; Joerger M
    Br J Clin Pharmacol; 2021 Feb; 87(2):306-316. PubMed ID: 33247980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
    Andriguetti NB; Raymundo S; Antunes MV; Perassolo MS; Verza SG; Suyenaga ES; Linden R
    Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of drug formulation on OATP1B-mediated transport of paclitaxel.
    Nieuweboer AJ; Hu S; Gui C; Hagenbuch B; Ghobadi Moghaddam-Helmantel IM; Gibson AA; de Bruijn P; Mathijssen RH; Sparreboom A
    Cancer Res; 2014 Jun; 74(11):3137-45. PubMed ID: 24755470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
    Krens SD; McLeod HL; Hertz DL
    Pharmacogenomics; 2013 Apr; 14(5):555-74. PubMed ID: 23556452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging as a pharmacodynamic marker.
    van der Veldt AA; Lammertsma AA
    Clin Cancer Res; 2014 May; 20(10):2569-77. PubMed ID: 24831279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
    de Weger VA; Beijnen JH; Schellens JH
    Anticancer Drugs; 2014 May; 25(5):488-94. PubMed ID: 24637579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
    Aapro M; Tjulandin S; Bhar P; Gradishar W
    Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes in elderly breast cancer patients.
    Wildiers H; Paridaens R
    Cancer Treat Rev; 2004 Jun; 30(4):333-42. PubMed ID: 15145508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
    de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
    Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions with the taxanes: clinical implications.
    Baker AF; Dorr RT
    Cancer Treat Rev; 2001 Aug; 27(4):221-33. PubMed ID: 11545542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.